Safety and Differential Antibody and T-Cell Responses to the <i>Plasmodium falciparum</i> Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.

导出 OA

翻译打印收藏纠错

作者： Said A,Jongo ^[1] ; L W Preston,Church ^[2] ; Ali T,Mtoro ^[1] ; Sumana,Chakravarty ^[2] ; Adam J,Ruben ^[2] ; Phillip A,Swanson ^[3] ; Kamaka R,Kassim ^[1] ; Maximillian,Mpina ^[4] ; Anneth-Mwasi,Tumbo ^[5] ; Florence A,Milando ^[4] ; Munira,Qassim ^[5] ; Omar A,Juma ^[1] ; Bakari M,Bakari ^[1] ; Beatus,Simon ^[1] ; Eric R,James ^[1] ; Yonas,Abebe ^[1] ; Natasha,Kc ^[2] ; Elizabeth,Saverino ^[2] ; Linda,Gondwe ^[2] ; Fabian,Studer ^[2] ; Martina,Fink ^[4] ; Glenda,Cosi ^[5] ; Jill,El-Khorazaty ^[4] ; David,Styers ^[5] ; Robert A,Seder ^[4] ; Tobias,Schindler ^[5] ; Peter F,Billingsley ^[4] ; Claudia,Daubenberger ^[5] ; B Kim Lee,Sim ^[6] ; Marcel,Tanner ^[6] ; Thomas L,Richie ^[3] ; Salim,Abdulla ^[4] ; Stephen L,Hoffman ^[5]

作者单位： Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania. ^[1] Sanaria, Inc., Rockville, Maryland. ^[2] Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. ^[3] University of Basel, Basel, Switzerland. ^[4] Swiss Tropical and Public Health Institute, Basel, Switzerland. ^[5] The Emmes Corporation, Rockville, Maryland. ^[6] Protein Potential LLC, Rockville, Maryland. ^[7]